Paeonia Lactiflora Root

Dosage for Paeonia Lactiflora Root extract is highly individualized and must be determined by an allergy specialist based on the patient's sensitivity levels. There is no 'standard' dose for non-standardized extracts.

For Diagnostic Testing

• Percutaneous (Prick) Testing: Usually, a single drop of the most concentrated form (e.g., 1:10 or 1:20 w/v) is applied to the skin, followed by a skin prick. Results are read after 15–20 minutes.
• Intradermal Testing: If the prick test is negative, a healthcare provider may inject 0.02 mL to 0.05 mL of a highly diluted solution (e.g., 1:1000 or 1:500 w/v) into the skin.

For Immunotherapy

• Escalation Phase: Treatment typically starts with a very low dose (e.g., 0.05 mL of a 1:100,000 w/v dilution) and increases weekly or bi-weekly.
• Maintenance Phase: Once the 'top dose' is reached (the highest dose the patient can tolerate without a systemic reaction), injections are given every 2–4 weeks. Maintenance doses often range from 0.2 mL to 0.5 mL of a 1:100 or 1:10 w/v solution.

Paeonia Lactiflora Root extract may be used in children, but extreme caution is required. Dosing is generally based on the same principles of sensitivity as adult dosing, rather than weight-based calculations. However, children under the age of 5 may be at a higher risk for systemic reactions and may have difficulty communicating early symptoms of anaphylaxis. Healthcare providers typically evaluate the risk-benefit ratio carefully for pediatric patients.

Renal Impairment

No specific dosage adjustments are typically required for renal impairment, as the extract is not primarily cleared through the kidneys in its active form. However, the patient's overall health must be stable.

Hepatic Impairment

No specific adjustments are documented for hepatic impairment. The metabolic breakdown of proteins is generally independent of primary liver enzyme pathways (like CYP450).

Elderly Patients

Elderly patients may have a higher prevalence of cardiovascular disease, which can make the use of epinephrine (the treatment for a severe reaction) more dangerous. Healthcare providers may use more conservative dosing increments for older adults.

This medication is NEVER for self-administration at home. It must be administered in a clinical setting equipped with emergency resuscitation equipment.

• With/Without Food: Food intake does not interfere with the injection, but it is recommended to avoid heavy meals or vigorous exercise immediately before or after the injection to minimize the risk of rapid systemic absorption.
• Administration: The injection is given subcutaneously (just under the skin), usually in the back of the upper arm. The site should not be massaged after injection.
• Storage: Vials must be stored in a refrigerator between 2°C and 8°C (36°F to 46°F). They must not be frozen.

If a dose in an immunotherapy schedule is missed, the next dose may need to be reduced depending on how much time has passed.

• 1–2 weeks late: The dose may remain the same.
• 3–4 weeks late: The dose is often reduced to the previous level.
• Over 4 weeks late: The healthcare provider may need to restart the escalation or significantly reduce the dose to ensure safety.

An overdose of Paeonia Lactiflora Root extract refers to the administration of a dose that exceeds the patient's current tolerance level.

• Signs of Overdose: Rapid onset of hives (urticaria), swelling of the throat (angioedema), wheezing, shortness of breath, and a drop in blood pressure (hypotension).
• Emergency Measures: Immediate administration of epinephrine, oxygen, and IV fluids. Patients must be monitored for at least 30 minutes after every injection to catch these signs early.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose without medical guidance.

Most patients receiving Paeonia Lactiflora Root extract will experience some form of local reaction. These are generally not dangerous but can be uncomfortable.

• Local Redness (Erythema): A red patch at the injection site that usually appears within minutes and may last for several hours.
• Swelling (Edema): A raised 'knot' or bump at the injection site. If the swelling is smaller than the size of a half-dollar (approx. 3 cm), it is considered a normal local reaction.
• Itching (Pruritus): Intense itching at the site of administration is very common as the body reacts to the allergen.
• Tenderness: The area may feel sore or bruised for 24–48 hours following the injection.

• Large Local Reactions: Swelling that exceeds 5–10 cm in diameter. While not life-threatening, these often require a dosage adjustment for the next visit.
• Fatigue: Some patients report feeling unusually tired for a few hours after their allergy injection.
• Headache: Mild to moderate headaches may occur shortly after administration.
• Nasal Congestion: A mild increase in hay fever-like symptoms shortly after the dose.

• Generalized Hives: Itching and red bumps appearing on parts of the body far from the injection site.
• Nausea and Abdominal Cramping: Early systemic signs that the body is reacting too strongly to the dose.
• Persistent Cough: A sign of mild airway irritation.

> Warning: Stop taking Paeonia Lactiflora Root and call your doctor immediately if you experience any of these.

• Anaphylaxis: A life-threatening allergic reaction involving multiple organ systems. Symptoms include a rapid pulse, difficulty breathing, and a feeling of 'impending doom.'
• Angioedema: Severe swelling of the lips, tongue, or throat that can obstruct the airway.
• Bronchospasm: Severe wheezing or chest tightness that makes it difficult to move air in and out of the lungs.
• Hypotension: A sudden, dangerous drop in blood pressure that can lead to fainting or shock.
• Cyanosis: A bluish tint to the skin or lips, indicating a lack of oxygen.

With prolonged immunotherapy use, the primary long-term effect is the desired desensitization. However, some patients may develop a chronic sensitivity at the injection site, characterized by small, persistent subcutaneous nodules (granulomas). These are rare and usually resolve over several months. There is no evidence that long-term use of plant allergenic extracts increases the risk of cancer or autoimmune disease.

While Paeonia Lactiflora Root may not have a specific individual black box warning, the entire class of Allergenic Extracts carries a general FDA-mandated warning regarding the risk of severe systemic reactions.

Summary of Warning: Allergenic extracts can cause severe life-threatening systemic reactions, including anaphylaxis. They should only be administered by healthcare professionals prepared to manage such reactions. Patients with unstable asthma are at increased risk for fatal reactions. Certain medications, such as beta-blockers, may make a patient's reaction more difficult to treat.

Report any unusual symptoms to your healthcare provider.

Paeonia Lactiflora Root extract is a potent biological substance. It is intended only for use by physicians who are experienced in the administration of allergenic extracts and the treatment of allergic diseases. Because of the risk of systemic reactions, patients must remain in the medical office for at least 30 minutes following any injection.

No specific FDA black box warning exists uniquely for Paeonia Lactiflora Root; however, it falls under the class-wide warning for all allergenic extracts. This warning emphasizes that these products can cause anaphylaxis, which may be fatal. It also notes that patients with severe or poorly controlled asthma are at a significantly higher risk for life-threatening complications.

• Allergic Reactions / Anaphylaxis Risk: This is the primary concern. Any history of a previous severe reaction to peony-derived products is a major warning sign. The risk is higher during the 'build-up' or escalation phase of treatment.
• Asthma Status: If you have asthma, it must be well-controlled before you receive an injection. If you are experiencing an asthma flare-up or your peak flow meter readings are low, your doctor will likely postpone your dose.
• Beta-Blocker Use: Patients taking beta-blockers (medications for blood pressure or heart conditions) may not respond well to epinephrine if they have an allergic reaction. This makes the use of Paeonia Lactiflora Root significantly more dangerous.
• Acute Illness: If you have a fever or a respiratory infection, your healthcare provider may delay your injection until you have recovered, as illness can lower the threshold for a systemic allergic reaction.

• Observation Period: A mandatory 30-minute wait in the clinic after every dose.
• Lung Function: For asthmatic patients, a peak flow or spirometry test may be required before each injection.
• Injection Site Inspection: The healthcare provider will check the site of the previous injection for large local reactions before administering a new dose.

Most patients can drive after the 30-minute observation period. However, if you feel lightheaded, dizzy, or extremely fatigued after your injection, you should avoid driving or operating heavy machinery until these symptoms completely resolve.

Alcohol consumption should be avoided on the day of your injection. Alcohol can dilate blood vessels and potentially increase the rate at which the allergen is absorbed into your bloodstream, increasing the risk of a systemic reaction.

If you decide to stop immunotherapy, there is no 'withdrawal' syndrome. However, your allergy symptoms may return to their baseline levels over time. If treatment is stopped for more than a few weeks and then restarted, the dose must be significantly lowered to prevent a reaction.

> Important: Discuss all your medical conditions with your healthcare provider before starting Paeonia Lactiflora Root.

• Beta-Adrenergic Blockers (Beta-Blockers): These include drugs like propranolol, atenolol, and metoprolol. They are contraindicated because they interfere with the action of epinephrine. If a patient on a beta-blocker has anaphylaxis from Paeonia Lactiflora Root, the standard emergency treatment (epinephrine) may be ineffective, leading to a potentially fatal outcome.

• ACE Inhibitors: Medications like lisinopril or enalapril may increase the risk of severe systemic reactions or worsen the symptoms of anaphylaxis.
• MAO Inhibitors (MAOIs): Drugs like phenelzine used for depression can increase the cardiovascular effects of epinephrine, complicating the management of a reaction.
• Tricyclic Antidepressants: Similar to MAOIs, these can potentiate the effects of epinephrine, leading to dangerous heart rhythms if a reaction occurs.

• Antihistamines: Drugs like cetirizine, loratadine, or diphenhydramine can mask the early signs of an allergic reaction (like itching or hives). While they don't prevent anaphylaxis, they can delay its recognition. Patients are often told to avoid antihistamines for 48–72 hours before a diagnostic skin test.
• Systemic Corticosteroids: Long-term use of prednisone may suppress the immune response to the extract, potentially reducing the efficacy of both skin testing and immunotherapy.

• Alcohol: As mentioned, alcohol can increase the risk of a systemic reaction by increasing blood flow and absorption rates.
• Heavy/High-Fat Meals: While not a direct chemical interaction, very heavy meals immediately before an injection can cause gastrointestinal discomfort that might be confused with the early signs of an allergic reaction.

• St. John's Wort: May have minor interactions with the way the body handles stress and blood pressure, potentially complicating the response to an allergic event.
• Ginkgo Biloba: Known for its mild anti-platelet effects, it could theoretically increase bruising at the injection site.

• Skin Prick Tests: Paeonia Lactiflora Root is itself used for testing. Other drugs (like antihistamines or certain antidepressants) will interfere with the results of these tests, leading to 'false negatives.'

For each major interaction, the mechanism usually involves either a pharmacodynamic interaction (where the drugs have opposing or synergistic effects on the heart and lungs) or a masking effect that prevents the timely identification of a medical emergency. The management strategy is always to ensure the patient's medication list is fully reviewed by the allergist before the first dose is administered.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking.

• Severe, Uncontrolled Asthma: Patients whose asthma is not stable are at the highest risk for a fatal reaction. The bronchoconstriction from an allergic reaction combined with pre-existing asthma can be irreversible.
• Recent Myocardial Infarction (Heart Attack): Within the last 3–6 months. The stress of a potential systemic reaction and the subsequent need for epinephrine could cause further heart damage.
• Hypersensitivity to Diluent Ingredients: Some extracts contain phenol or glycerin as preservatives. If a patient is known to be allergic to these specific chemicals, the extract must not be used.
• Inability to Communicate: Patients who cannot report early symptoms of a reaction (e.g., very young children or those with certain cognitive impairments) may be considered to have an absolute contraindication in some clinical settings.

• Pregnancy: While not strictly forbidden, starting new immunotherapy during pregnancy is generally avoided due to the risk of anaphylaxis-induced fetal hypoxia (lack of oxygen to the baby). If a patient is already on a stable maintenance dose, it may sometimes be continued.
• Autoimmune Disorders: Patients with active systemic lupus or rheumatoid arthritis may have unpredictable immune responses to allergenic extracts.
• Beta-Blocker Therapy: As detailed in the interactions section, this is a major relative contraindication that requires a careful risk-benefit analysis.

Patients allergic to Paeonia Lactiflora Root may also show cross-sensitivity to other members of the Paeoniaceae family. There is also anecdotal evidence of cross-reactivity with certain other spring-blooming ornamental plants, though this must be confirmed through specific clinical testing.

> Important: Your healthcare provider will evaluate your complete medical history before prescribing Paeonia Lactiflora Root.

Paeonia Lactiflora Root extract is generally classified as Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women. The primary risk is not the extract itself, but the potential for a systemic allergic reaction (anaphylaxis) in the mother. Anaphylaxis can lead to a sudden drop in blood pressure and uterine contractions, which may cause fetal distress or miscarriage. Most allergists will not start a new 'build-up' phase during pregnancy but may continue maintenance doses if the patient is stable and the risk of stopping treatment (e.g., severe asthma from allergies) outweighs the risk of the injection.

It is not known whether the protein components of Paeonia Lactiflora Root extract are excreted in human milk. However, because these are large proteins that are broken down locally, it is considered unlikely that they would reach the infant in significant amounts via breast milk. Breastfeeding is generally not considered a reason to stop immunotherapy, but you should discuss this with your doctor.

Paeonia Lactiflora Root extract is used in children, but the safety and efficacy have not been established in very young children (typically those under age 5). The main challenge in pediatric use is the child's ability to cooperate with the 30-minute wait and their ability to describe early symptoms of a reaction, such as an itchy throat or 'funny' feeling in the chest.

Patients over the age of 65 may be at higher risk for complications if a systemic reaction occurs. Older adults are more likely to have underlying cardiovascular disease, which increases the risk of heart rhythm issues if epinephrine must be administered. The healthcare provider will perform a thorough cardiovascular screening before starting immunotherapy in an elderly patient.

There are no specific guidelines for renal impairment. Because the extract consists of proteins that are metabolized by proteases throughout the body, the kidneys do not play a primary role in the clearance of the active components. However, patients with end-stage renal disease should be monitored for overall fluid balance and stability.

Hepatic impairment does not typically affect the metabolism of allergenic extracts. No dosage adjustments are usually required for patients with liver disease, provided they are otherwise stable and able to tolerate potential emergency treatments.

> Important: Special populations require individualized medical assessment.

Paeonia Lactiflora Root extract works through the induction of immunological tolerance. In the diagnostic phase, it identifies the presence of allergen-specific IgE antibodies bound to mast cells. In the therapeutic phase, repeated exposure to the antigen leads to a decrease in the Th2 cell response and an increase in Th1 and T-regulatory cell activity. This leads to the production of IgG4 'blocking antibodies' which compete with IgE for the allergen, thereby preventing the allergic cascade.

The dose-response relationship in allergenic extracts is highly individual. The time to onset for a skin test is 15–20 minutes. For immunotherapy, the duration of effect can last for several years after a 3-to-5-year course of treatment is completed. Tolerance develops gradually over the first 6–12 months of therapy.

| Parameter | Value |

|---|---|

| Bioavailability | Low (primarily local) |

| Protein Binding | Not applicable (proteins are the active agents) |

| Half-life | Varies by protein (typically hours at the site) |

| Tmax | 15–30 minutes (local reaction) |

| Metabolism | Proteolysis by local and lymphatic enzymes |

| Excretion | Minimal renal excretion of metabolites |

The extract is a complex mixture of proteins, glycoproteins, and polysaccharides. The primary bioactive component of the root itself is often cited as Paeoniflorin (C23H28O11), though the allergenic extract contains the full spectrum of water-soluble proteins from the root. The molecular weight of the allergenic proteins typically ranges from 10,000 to 70,000 Daltons. It is soluble in aqueous buffers used for clinical injections.

Paeonia Lactiflora Root belongs to the class of Non-Standardized Plant Allergenic Extracts. Related medications include other non-standardized extracts such as Oak, Hickory, or various flower extracts used in allergy diagnostics.